Molecular Laboratory Billing Services
Molecular Lab Billing That Captures Every Reimbursement Your Testing Revenue Deserves
Molecular laboratory billing is one of the most technically demanding revenue cycle environments in all of healthcare. Tier 1 and Tier 2 molecular pathology codes, PLA codes, LCD/NCD compliance, payer-specific molecular testing policies, and prior authorization requirements that change by payer, by test, and by diagnosis make it genuinely unlike any other billing specialty.
Measurable Revenue Outcomes for Molecular Laboratory
.png)
< 30
97%
12–18%
99%
98%
Average Days in AR
Collection Ratios
Revenue Improvement
First Pass Ratio
Clean Claims Accuracy
End-to-End Molecular Lab Revenue Cycle
Our Molecular Laboratory Billing Services Complete Coverage, Every Test Type
We manage the complete revenue cycle for molecular laboratories from test order intake through final payment with the specialty depth that molecular pathology billing demands and the consistency that high-volume lab operations require.
Insurance Verification & Benefits
Real-time eligibility checks that confirm active coverage, identify molecular testing benefit levels, flag MAPY (maximum allowable payment year) limitations, and detect any payer-specific molecular testing exclusions before the specimen is processed. Problems found before testing saves weeks of post-service denial management.
Prior Authorization Management
We manage the full PA workflow for every molecular test that requires authorization NGS panels, pharmacogenomics testing, hereditary cancer panels, and other high-value molecular services. Our team tracks which tests require PA at which payers, submits the authorization request with the clinical documentation the payer requires, and follows up through the approval process before the test is reported.
Molecular Pathology Medical Coding
Our certified coders apply the correct molecular pathology CPT code — Tier 1, Tier 2, GSP, or PLA — based on the specific analyte, methodology, and technical complexity of each test. We maintain a test-specific code mapping for your entire test menu, updated as CMS publishes annual molecular pathology code revisions and as new PLA codes are assigned.
LCD/NCD Compliance Review
Every molecular claim goes through an LCD compliance check before submission verifying that the ordering diagnosis codes satisfy the covered indication language in the applicable LCD, that any required clinical documentation or attestation is present, and that the claim meets MolDX program requirements for Medicare billing. Non-compliant claims are corrected or held before submission, not denied after.
Clean Claim Submission
Every molecular lab claim passes through a structured scrub molecular code accuracy, LCD diagnosis alignment, PA verification, frequency limitation check, modifier application, and NCCI edit compliance before electronic submission. Our 98% first-pass clean claim rate reflects a process built specifically around molecular laboratory billing failure points, not a generic medical billing checklist.
Payment Posting & Reconciliation
Every payment — ERA, EFT, and paper is posted accurately and reconciled against contracted reimbursement rates for each test code. Underpayments are identified and disputed before they're written off. Patient responsibility is transferred correctly after insurance processing. You have real-time visibility into where every dollar from every test is sitting in your revenue cycle at any point.
Denial Management & Technical Appeals
Molecular lab denials require technical knowledge to appeal effectively understanding the difference between a medical necessity denial that needs additional clinical documentation versus an LCD non-compliance denial that requires a corrected claim versus a frequency limitation denial that needs patient history documentation. We investigate each denial at the root cause and build complete appeals that address the specific adjudication failure, not a generic reconsideration letter.
AR Follow-Up & Revenue Analytics
We work your molecular lab AR with structured priority-based follow-up ranking claims by dollar value, payer response pattern, and proximity to filing deadlines. Monthly analytics provide revenue by test type, denial patterns by payer and reason code, AR aging by service category, and collection rate trends by test panel giving you the financial visibility to manage the lab's revenue cycle proactively.
Why Molecular Laboratories Choose MedCloudMD
✔ MedCloudMD AI Revenue Intelligence
✔ Molecular Pathology Is Our Core Specialty
✔ Proactive LCD and Payer Policy Monitoring
✔ Test-Specific Code Mapping Built for Your Lab
✔ Technical-Level Denial Appeals
✔ Dedicated Lab Account Manager
✔ Seamless EHR & Practice Management Integration
The Billing Failures Costing Molecular Labs Significant Revenue Every Month
Why it happens: The physician order doesn't explicitly reference the diagnosis language required by the applicable LCD.
LCD policies for molecular tests don't just require a diagnosis they often require specific ICD-10 codes within defined code ranges, specific clinical circumstances documented in the ordering physician's notes, and sometimes attestation language that must appear in the requisition. When any of these elements are missing or imprecise, the claim hits a medical necessity denial. For high-cost molecular panels, a single missed LCD element on a claim worth $1,200 to $4,000 is a significant per-claim revenue loss.
✓ MedCloudMD Solution: Pre-submission LCD compliance review on every molecular claim before it leaves the lab
Incorrect Tier Selection on Molecular Pathology Codes
Why it happens: The billing team applies the wrong tier level based on general coding knowledge rather than molecular testing specificity.
A test billed under a Tier 2 code that should be a Tier 1 code or vice versa results in either a technical denial or incorrect reimbursement. For laboratories running dozens of different test types across both tier levels, systematic tier selection errors create a compounding revenue accuracy problem that's invisible in denial reporting because many of the incorrectly tiered claims are actually paid at the wrong rate rather than denied outright.
✓ MedCloudMD Solution: Test-specific code mapping built from your actual test menu, not generic coding decisions
Missing PLA Codes for Proprietary Tests
Why it happens: Lab billing teams don't identify that a test has an assigned PLA code and bill generic codes instead.
Many molecular tests particularly pharmacogenomics panels, hereditary cancer panels, and proprietary carrier screening products have assigned PLA codes that are specific to that test from that laboratory or manufacturer. Billing a generic Tier 2 code for a test that has a PLA code means the claim is adjudicated under a different reimbursement structure than the test is entitled to. In some cases, the generic code isn't covered at all by certain payers when a PLA code exists for the test.
✓ MedCloudMD Solution: Comprehensive PLA code review against your specific test menu during onboarding
Prior Authorization Failures for NGS and High-Value Panels
Why it happens: Commercial payers require PA for NGS, pharmacogenomics, and hereditary cancer testing and lab billing teams don't consistently track which tests require authorization at which payers.
Next-generation sequencing panels and broad hereditary disease panels can generate claims ranging from $1,500 to $10,000 or more. Most major commercial payers require prior authorization for these tests, and the authorization must be obtained using the ordering physician's clinical information not the lab's test description. When PA is missed, the test is denied post-service in a way that's rarely recoverable, and the revenue from one missed authorization can offset dozens of correctly processed routine claims.
✓ MedCloudMD Solution: Payer-by-test PA requirement matrix with proactive authorization management before processing
Frequency Limitation Denials
Why it happens: Tests are run and billed without checking payer frequency rules that limit how often a specific molecular test can be billed for a patient.
Medicare and commercial payers often apply frequency limitations to molecular tests particularly pharmacogenomics tests, which Medicare generally limits to once per lifetime for many codes, and infectious disease panels, which may be limited by episode or by time period. Running the same test within the limitation window generates an automatic denial. Without per-patient test history tracking integrated into the billing workflow, labs bill these tests repeatedly without realizing the reimbursement window has already closed.
✓ MedCloudMD Solution: Per-patient test history tracking against payer-specific frequency limitations before billing
Timely Filing Losses on Denied Claims
Why it happens: Denied molecular claims sit in AR without aggressive follow-up until the filing deadline for the corrected claim or appeal passes.
Molecular lab claims that are denied for correctable reasons a missing diagnosis code, an incomplete requisition, or a fixable authorization issue can be resubmitted or appealed within the payer's timely filing window. But when the billing team doesn't have the expertise to identify what specifically needs to be corrected, or doesn't prioritize high-value molecular claims in the follow-up queue, the appeal deadline passes and the revenue is permanently lost. For labs with high-value test menus, unworked denied claims aging past filing deadlines represent serious accumulated revenue losses.
✓ MedCloudMD Solution: Priority-based AR follow-up with molecular-specific denial resolution expertise
MedCloudMD AI Built to Handle the Complexity of Molecular Lab Revenue Cycles
Our proprietary AI platform runs continuously across your laboratory revenue cycle cross-referencing every test against current payer policies, LCD requirements, frequency limitations, and PA status before a single claim leaves the lab.
PA Requirement Detection
MedCloudMD AI maintains a continuously updated payer-by-test PA requirement matrix identifying which tests require authorization at which payers before the test is processed. PA alerts are generated automatically so your team can initiate authorization requests early enough to avoid post-service PA denials on high-value molecular panels.
Frequency Limitation Monitoring
MedCloudMD AI tracks each patient's test history against payer-specific frequency limitations flagging tests that have already been billed within a limitation window before the order is processed. Frequency violation denials are among the most preventable in molecular lab billing, and our system prevents them automatically rather than discovering them in the denial queue.
LCD Compliance Screening
MedCloudMD AI cross-references every molecular claim against the applicable LCD for that test verifying diagnosis code compliance, clinical indication documentation, and MolDX registration status before submission. Claims that don't satisfy LCD requirements are flagged for correction before they reach CMS, not after they return as non-covered denials.
Revenue Forecasting by Test Type
Your analytics dashboard shows revenue by test category, collection rates by payer, denial trends by molecular test type, and forward-looking revenue projections based on current order volume and payer mix. Lab directors and administrators always have the financial data they need to make test menu, pricing, and payer contract decisions.
Smart AR Prioritization
At molecular lab volumes, manual AR follow-up misses high-value claims buried in the queue. MedCloudMD AI ranks every aging molecular claim by dollar value, payer response pattern, and days until filing deadline so your follow-up effort goes toward the tests most likely to recover significant revenue before appeal windows close.
PLA Code Identification
MedCloudMD AI cross-checks your test menu against the current PLA code master file and identifies every test that has an assigned proprietary code that should be billed instead of a generic molecular pathology code. As new PLA codes are assigned quarterly by AMA, the system flags any additions that affect your specific test menu automatically.
Why Molecular Laboratory Billing Is Unlike Any Other Specialty in Healthcare
If you've tried to use a general medical billing company or a hospital-focused RCM team for your molecular laboratory, you already know the result. They process the claim. The payer returns it with a medical necessity denial, a frequency limitation edit, or a simple non-covered service remark and no one on the billing side knows why, because they don't know the difference between a Tier 1 code that follows its own technical complexity hierarchy and a PLA code that requires a specific analyte-specific reagent linkage in the documentation.
Molecular laboratory billing operates under a coding and coverage framework that took years to construct and continues to evolve. CMS created a tiered molecular pathology code structure specifically because the complexity and clinical utility of different molecular tests vary enormously from a single nucleotide polymorphism analysis on the low end to whole genome sequencing on the other. The billing for each level has distinct documentation requirements, distinct medical necessity criteria, and distinct payer policy implications that a generalist billing team simply hasn't been trained to navigate.
Beyond the coding complexity, the coverage landscape creates an additional layer of difficulty. The MolDX program, administered by Palmetto GBA and Noridian as the Medicare Administrative Contractors for molecular testing, governs reimbursement for the vast majority of molecular pathology tests billed to Medicare. MolDX requires test-specific coverage determinations, often demands test registration, and publishes LCD policies that define in precise clinical terms when each test category is and isn't covered. Missing a MolDX requirement doesn't result in a soft denial it results in non-covered denials that are rarely recoverable retroactively.
And layered on top of all of that is the commercial payer environment where each major insurer maintains its own molecular testing coverage policies, its own prior authorization requirements for high-cost panels like next-generation sequencing and pharmacogenomics, and its own medical necessity criteria that don't align neatly with Medicare's coverage determinations. Billing molecular tests correctly across that entire payer landscape requires dedicated expertise that most billing teams don't have and can't develop without hands-on experience in laboratory RCM specifically.
Tiered Molecular Pathology Coding (Tier 1 and Tier 2)
Accurate Tier 1 and Tier 2 CPT code selection is essential for proper reimbursement. We ensure every molecular test is coded based on its complexity and clinical requirements.
We help laboratories meet MolDX coverage guidelines by verifying documentation and medical necessity. This reduces Medicare denials and supports faster claim approvals.
MolDX Program Coverage Requirements
Our team ensures every molecular test meets LCD and NCD medical necessity requirements. Proper diagnosis and documentation help maximize reimbursement and minimize denials.
LCD and NCD Medical Necessity Compliance
We monitor payer frequency limits and bundling rules to prevent avoidable claim denials. Accurate billing keeps your molecular testing claims compliant and reimbursable.We handle the process to reduce delays and paperwork.
Frequency Limitations and Panel Bundling Rules
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
Your Molecular Tests Are Generating Results That Change Patient Outcomes Make Sure the Billing Reflects Every Dollar of That Value
Incorrect tier assignments, missing PLA codes, LCD non-compliance, unmanaged prior authorizations, and frequency limitation violations are happening in most molecular labs right now quietly, repeatedly, and compounding into revenue losses that don't surface clearly in standard denial reports until someone with the right expertise looks at the data. Our free molecular lab billing audit identifies every gap in your current billing operation, puts a specific dollar estimate on each one, and shows you exactly what recovery looks like. No cost, no obligation, and no pressure to make any decision on the call.
Frequently asked questions
- 01
- 02
- 03
- 04
- 05
- 06